IVERIC bio Inc (ISEE)

Overview

IVERIC bio, Inc. is a biopharmaceutical enterprise that specializes in the development of innovative therapeutic solutions for various eye conditions. With a strong focus on age-related and rare inherited retinal diseases (IRDs), the company aims to push the boundaries of care for patients suffering from these conditions. IVERIC bio is particularly recognized for its development pipeline, which includes Zimura, an inhibitor that targets complement factor C5. Zimura is currently undergoing clinical trials for geographic atrophy (GA), known as a severe form of dry age-related macular degeneration (AMD). Moreover, the company's ongoing efforts include multiple clinical trials aimed at various inherited retinal diseases and advancing potential treatments from its diverse portfolio. Originally founded in 2007 as Ophthotech Corporation, IVERIC bio adopted its current name in April 2019, and its operations are based in Parsippany, New Jersey.

Products and Services

• Zimura: This is an inhibitor targeting complement factor C5, which is currently under investigation for treating geographic atrophy (GA) in patients with dry age-related macular degeneration (AMD). Zimura has successfully completed the Phase 2/3 GATHER1 trial and is in the Phase 3 stage of the GATHER2 trial.
• STAR (OPH2005): A candidate in Phase 2b clinical trials, STAR is being developed for the treatment of Leber congenital amaurosis type 10 (LCA10) and autosomal recessive Stargardt disease (STGD1), showing promise in addressing these rare retinal disorders.
• IC-500: This is a high-temperature requirement A serine peptidase 1 protein inhibitor that is designed for GA and other forms of age-related retinal degeneration. The development of IC-500 aims to provide a novel therapeutic option for patients suffering from these conditions.
• IC-100: Targeted towards rhodopsin-mediated autosomal dominant retinitis pigmentosa, IC-100 is focused on developing a therapy for a common genetic cause of inherited blindness.
• IC-200: This product is designed for inherited retinal diseases (IRDs) that are caused by mutations in the BEST1 gene, contributing to the company’s dedicated approach in addressing rare retinal disorders.
• Earlier Clinical Trials: IVERIC bio has completed several earlier-stage clinical trials including OPH2001 (Phase 1/2a study of Zimura monotherapy for GA), OPH2000 (Phase 1/2a trial for Zimura combined with Lucentis for wet AMD), OPH2007 (Phase 2a study for wet AMD), and OPH2002 (Phase 2a trial for idiopathic polypoidal choroidal vasculopathy).
• Research Programs: The company is also engaged in pioneering research efforts, exploring additional programs such as miniCEP290 for treating LCA10, miniABCA4 for STGD1, and miniUSH2A for Usher syndrome type 2A-related IRDs, further underpinning its commitment to advancing therapeutic options for patients with inherited retinal diseases.